GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amin Pharmaceutical Co (XTEH:AMIN1) » Definitions » Change In Working Capital

Amin Pharmaceutical Co (XTEH:AMIN1) Change In Working Capital : IRR0.00 Mil (TTM As of . 20)


View and export this data going back to 1990. Start your Free Trial

What is Amin Pharmaceutical Co Change In Working Capital?

Amin Pharmaceutical Co's change in working capital for the quarter that ended in . 20 was IRR0.00 Mil.

Amin Pharmaceutical Co's change in working capital for the fiscal year that ended in . 20 was IRR0.00 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).


Amin Pharmaceutical Co Change In Working Capital Historical Data

The historical data trend for Amin Pharmaceutical Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amin Pharmaceutical Co Change In Working Capital Chart

Amin Pharmaceutical Co Annual Data
Trend
Change In Working Capital

Amin Pharmaceutical Co Semi-Annual Data
Change In Working Capital

Amin Pharmaceutical Co Change In Working Capital Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Working Capital for the trailing twelve months (TTM) ended in . 20 was IRR0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amin Pharmaceutical Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Amin Pharmaceutical Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Amin Pharmaceutical Co (XTEH:AMIN1) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Abolfazl Street, Bostan Heftam West Alley, No. 4, 2nd floor, Marzdaran, Tehran, IRN
Amin Pharmaceutical Co is engaged in the manufacturing of pharmaceutical products, chemical drugs, herbal medicines, and nutritional supplements. It offers antimicrobials, cardiovascular, antidiabetic, cerebellar, gastrointestinal, antibiotic and antifungal, and hypoglycemic agents among others. It develops drugs in the form of plain and overlaid tablets, hard, and soft capsules, oral drops, syrups, and suspensions. Products offered by the company include Acarbose, Sitagliptin, Fampridine, Ofloxacin, Amiodarone, Ibuprofen, Zolpidem, Bilberry, Thyme, and others. Amin also exports its products to Afghanistan, Kazakhstan, Uzbekistan, and Iraq.

Amin Pharmaceutical Co (XTEH:AMIN1) Headlines

No Headlines